Regeneron Pharmaceuticals, Inc. (REGN) Cash Flow Statement
Regeneron Pharmaceuticals, Inc. (REGN) generated $4.7B of operating cash flow over the twelve months to 2026-06-30, spent $920.9M on capital expenditure and had free cash flow of $3.8B, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
REGNRegeneron Pharmaceuticals, Inc.Follow REGN — free
—
Price chart with a free account
- Market cap
- 82.9B
- P/E TTM
- 19.9
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 0.10 | -0.14 | -0.07 | 0.59 | 0.75 | 1.33 | 1.49 | 1.31 | 2.20 | 2.43 | 2.62 | 7.08 | 5.01 | 4.59 | 4.42 | 4.98 | 4.68 | |
| Capital expenditure | 0.10 | 0.06 | 0.05 | 0.16 | 0.33 | 0.68 | 0.51 | 0.27 | 0.38 | 0.43 | 0.61 | 0.55 | 0.59 | 0.72 | 0.76 | 0.90 | -0.92 | |
| Free cash flow | -0.00 | -0.20 | -0.12 | 0.43 | 0.42 | 0.65 | 0.97 | 1.03 | 1.81 | 2.00 | 2.00 | 6.53 | 4.42 | 3.88 | 3.66 | 4.08 | 3.76 | |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.37 | — | |
| Share repurchases | — | — | — | — | — | — | — | — | 0.00 | 0.28 | 5.85 | 1.65 | 2.08 | 2.24 | 2.60 | 3.44 | — | |
| Stock-based compensation | — | 0.06 | 0.09 | 0.22 | 0.32 | 0.46 | 0.56 | 0.51 | 0.43 | 0.46 | 0.43 | 0.60 | 0.73 | 0.89 | 0.98 | 0.99 | — |
USD billions · SEC XBRL
Regeneron Pharmaceuticals, Inc. — questions
- What is Regeneron Pharmaceuticals, Inc.'s operating cash flow?
- $4.7B over the twelve months to 2026-06-30.
- How much does Regeneron Pharmaceuticals, Inc. spend on capital expenditure?
- $920.9M over the twelve months to 2026-06-30.
- What is Regeneron Pharmaceuticals, Inc.'s free cash flow?
- $3.8B over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Regeneron Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.